| Budget Amount *help |
¥25,220,000 (Direct Cost: ¥19,400,000、Indirect Cost: ¥5,820,000)
Fiscal Year 2019: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2017: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2016: ¥10,400,000 (Direct Cost: ¥8,000,000、Indirect Cost: ¥2,400,000)
|
|---|
| Outline of Final Research Achievements |
This study aims to develop a new therapeutic method for amyloid diseases caused by aberrant protein aggregation. Thus, we have developed the methodology for suppressing the aggregation of amyloid proteins such as amyloid β (Aβ) responsible for Alzheimer's disease. Since the amyloid oligomers possessing the strong toxicity corresponds to the intermediate in the aggregation process, the rational design of the inhibitor based on the higher-order structure of amyloid oligomers is difficult. Therefore, in order to promote the structure-based inhibitor design, we aimed to obtain three-dimensional structure information on toxic oligomers of Aβ. In addition, we developed photo-catalysts that detoxified Aβ amyloid by the oxygenation using molecular oxygen as an oxygen atom donor.
|
